We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Review Suggests Investigator Bias in Amgen T-Vec Vaccine Study
FDA Review Suggests Investigator Bias in Amgen T-Vec Vaccine Study
The latest clinical trial results for Amgen’s talimogene laherparepvec immunotherapy may not be as strong as the company hoped, say FDA advisory committee briefing documents.